Investment Analysts’ Weekly Ratings Changes for Merus (MRUS)

Merus (NASDAQ: MRUS) has recently received a number of price target changes and ratings updates:

• 12/9/2024 – Merus had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a “buy” rating on the stock.
• 12/9/2024 – Merus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
• 12/3/2024 – Merus had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $109.00 price target on the stock, down previously from $111.00.
• 12/2/2024 – Merus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
• 12/2/2024 – Merus had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
• 11/21/2024 – Merus is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $73.00 price target on the stock.
• 11/20/2024 – Merus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
• 11/1/2024 – Merus had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
• 11/1/2024 – Merus had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
• 10/24/2024 – Merus is now covered by analysts at UBS Group AG. They set a “buy” rating and a $72.00 price target on the stock.

Merus Stock Up 1.4 %

Shares of NASDAQ:MRUS traded up $0.60 during midday trading on Monday, hitting $42.45. The stock had a trading volume of 326,354 shares, compared to its average volume of 682,061. The company has a market capitalization of $2.91 billion, a P/E ratio of -10.75 and a beta of 1.07. The company’s 50-day moving average price is $47.99 and its 200-day moving average price is $51.13. Merus has a fifty-two week low of $27.11 and a fifty-two week high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The company had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Research analysts expect that Merus will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its position in shares of Merus by 30.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 40,633 shares of the biotechnology company’s stock worth $2,404,000 after buying an additional 9,488 shares during the period. Legato Capital Management LLC bought a new position in shares of Merus in the 2nd quarter worth $616,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Merus by 41.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,847 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 2,572 shares during the period. Nicholas Investment Partners LP acquired a new position in Merus during the second quarter worth $4,763,000. Finally, First Turn Management LLC acquired a new position in shares of Merus during the second quarter valued at about $19,047,000. Institutional investors own 96.14% of the company’s stock.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.